The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Nanobodies as novel agents for cancer therapy
Abstract
Nanobodies are the smallest fragments of naturally occurring heavy-chain antibodies that have evolved to be fully functional in the absence of a light chain. As such, the cloning and selection of antigen-specific nanobodies obviate the need for construction and screening of large libraries, and for lengthy and unpredictable in vitro affinity maturation steps. The unique and well-characterised properties enable nanobodies to excel conventional therapeutic antibodies in terms of recognising uncommon or hidden epitopes, binding into cavities or active sites of protein targets, tailoring of half-life, drug format flexibility, low immunogenic potential and ease of manufacture. Moreover, the favourable biophysical and pharmacological properties of nanobodies, together with the ease of formatting them into multifunctional protein therapeutics, leaves them ideally placed as a new generation of antibody-based therapeutics. This review describes the state of the art on nanobodies and illustrates their potential as cancer therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Sequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241 · cited 1×
“Part of the humoral response of camels, dromedaries and llamas is based on a unique repertoire of fully functional antibodies composed solely of heavy chains (Figure 1) [40].”
BackgroundSelf-citationMaking antibodies by phage display technology
Winter, G., Griffiths, A. D., Hawkins, R. E., & Hoogenboom, H. R. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002245 · Cited by 1,573
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Ward, E. S., Güssow, D., Griffiths, A. D., Jones, P. T., & Winter, G. (1989) · Nature · doi:10.1038/341544a0 · Cited by 1,003
Winter, G., & Milstein, C. (1991) · Nature · doi:10.1038/349293a0 · Cited by 945
Therapeutic strategies for rheumatoid arthritis
Smolen, J. S., & Steiner, G. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1109 · Cited by 911
Anatomy of the antibody molecule
Padlan, E. A. (1994) · Molecular Immunology · doi:10.1016/0161-5890(94)90001-9 · Cited by 896
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Yokota, T., Milenic, D. E., Whitlow, M. D., & Schlom, J. (1992) · PubMed · Cited by 819
Greenberg, A. S., Avila, D., Hughes, M., Hughes, A., McKinney, E. C., & Flajnik, M. F. (1995) · Nature · doi:10.1038/374168a0 · Cited by 775
Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies
Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R., & Muyldermans, S. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01062-4 · Cited by 768
Self-citationCloning immunoglobulin variable domains for expression by the polymerase chain reaction.
Orlandi, R., Güssow, D. H., Jones, P. T., & Winter, G. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3833 · Cited by 706
Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., & Anderson, C. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021829 · Cited by 640
Single‐domain antibody fragments with high conformational stability
Dumoulin, M., Conrath, K., Van Meirhaeghe, A., Meersman, F., Heremans, K., Frenken, L. G. J., Muyldermans, S., Wyns, L., & Matagne, A. (2002) · Protein Science · doi:10.1110/ps.34602 · Cited by 638
Self-citationAntibodies, viruses and vaccines
Burton, D. R. (2002) · Nature Reviews Immunology · doi:10.1038/nri891 · Cited by 637
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629
Stability engineering of antibody single-chain Fv fragments
Wörn, A., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4265 · Cited by 616
Therapeutic Strategies for Rheumatoid Arthritis
O'Dell, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040226 · Cited by 588
The fibronectin type III domain as a scaffold for novel binding proteins
Koide, A., Bailey, C. W., Huang, X., & Koide, S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2238 · Cited by 585 · cited 1×
“In addition, other scaffolds of similar size as camelid nanobodies have been employed to generate single-domain antigen binders, such as the FN3 domain or the cytotoxic T lymphocyte antigen-4 [72-74].”
BackgroundEscherichia coli Secretion of an Active Chimeric Antibody Fragment
Better, M., Chang, C. P., Robinson, R. R., & Horwitz, A. H. (1988) · Science · doi:10.1126/science.3285471 · Cited by 579
PEGylated antibodies and antibody fragments for improved therapy: a review
Chapman, A. P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00026-1 · Cited by 556
Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme
Desmyter, A., Transue, T. R., Ghahroudi, M. A., Dao Thi, M.-H., Poortmans, F., Hamers, R., Muyldermans, S., & Wyns, L. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0996-803 · Cited by 522
Self-citationSelection of phage antibodies by binding affinity
Hawkins, R. E., Russell, S. J., & Winter, G. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90639-2 · Cited by 520
Antibody phage display technology and its applications
Hoogenboom, H. R., de Bruı̈ne, A. P., Hufton, S. E., Hoet, R. M., Arends, J.-W., & Roovers, R. C. (1998) · Immunotechnology · doi:10.1016/s1380-2933(98)00007-4 · Cited by 512
Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins
Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., & Damico, L. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205854200 · Cited by 508
Muyldermans, S., Atarhouch, T., Saldanha, J., Barbosa, J. A. R. G., & Hamers, R. (1994) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/7.9.1129 · Cited by 494
Self-citationPotent enzyme inhibitors derived from dromedary heavy-chain antibodies
Lauwereys, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.13.3512 · Cited by 490
van der Linden, R. H. J., Frenken, L. G. J., de Geus, B., Harmsen, M. M., Ruuls, R. C., Stok, W., de Ron, L., Wilson, S., Davis, P., & Verrips, C. T. (1999) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(99)00030-8 · Cited by 471
Sandborn, W. J., & Hanauer, S. B. (1999) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199905000-00008 · Cited by 454
Protein clefts in molecular recognition and function.
Laskowski, R. A., Luscombe, N. M., Swindells, M. B., & Thornton, J. M. (1996) · PubMed · doi:10.1002/pro.5560051206 · Cited by 407
By–Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling
Marks, J. D., Griffiths, A. D., Malmqvist, M., Clackson, T. P., Bye, J. M., & Winter, G. (1992) · Nature Biotechnology · doi:10.1038/nbt0792-779 · Cited by 404
Hudson, P. J., & Souriau, C. (2003) · Nature Medicine · doi:10.1038/nm0103-129 · Cited by 398
Efficient Cancer Therapy with a Nanobody-Based Conjugate
Cortez-Retamozo, V., Backmann, N., Senter, P. D., Wernery, U., De Baetselier, P., Muyldermans, S., & Revets, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3935 · Cited by 382
Self-citationComparison of llama VH sequences from conventional and heavy chain antibodies
Vu, K. B., Ghahroudi, M. A., Wyns, L., & Muyldermans, S. (1997) · Molecular Immunology · doi:10.1016/s0161-5890(97)00146-6 · Cited by 343
Self-citationBiophysical Properties of Human Antibody Variable Domains
Ewert, S., Huber, T., Honegger, A., & Plückthun, A. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01237-8 · Cited by 330
Muyldermans, S., Cambillau, C., & Wyns, L. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01790-x · Cited by 322
Self-citationAn improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability
Whitlow, M., Bell, B. A., Feng, S.-L., Filpula, D., Hardman, K. D., Hubert, S. L., Rollence, M. L., Wood, J. F., Schott, M. E., Milenic, D. E., et al. (1993) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/6.8.989 · Cited by 318
Waibel, R., Alberto, R., Willuda, J., Finnern, R., Schibli, R., Stichelberger, A., Egli, A., Abram, U., Mach, J.-P., Plückthun, A., et al. (1999) · Nature Biotechnology · doi:10.1038/12890 · Cited by 303
Human Immune Respone to Monoclonal Antibodies
Khazaeli, M. B., Conry, R. M., & LoBuglio, A. F. (1994) · Journal of Immunotherapy · doi:10.1097/00002371-199401000-00006 · Cited by 301
Els Conrath, K., Lauwereys, M., Wyns, L., & Muyldermans, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007734200 · Cited by 300
Self-citationNguyen, V. K., Hamers, R., Wyns, L., & Muyldermans, S. (2000) · The EMBO Journal · doi:10.1093/emboj/19.5.921 · Cited by 299
Self-citationCrystal Structure of a Shark Single-Domain Antibody V Region in Complex with Lysozyme
Stanfield, R. L., Dooley, H., Flajnik, M. F., & Wilson, I. A. (2004) · Science · doi:10.1126/science.1101148 · Cited by 297
Bacteria as tumour-targeting vectors
Pawelek, J. M., Low, K. B., & Bermudes, D. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01194-x · Cited by 290
Frenken, L. G. J., van der Linden, R. H. J., Hermans, P. W. J. J., Bos, J. W., Ruuls, R. C., de Geus, B., & Verrips, C. T. (2000) · Journal of Biotechnology · doi:10.1016/s0168-1656(99)00228-x · Cited by 286
Length distribution of CDRH3 in antibodies
Wu, T. T., Johnson, G., & Kabat, E. A. (1993) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340160102 · Cited by 284
Efficient Targeting of Conserved Cryptic Epitopes of Infectious Agents by Single Domain Antibodies
Stijlemans, B., Conrath, K., Cortez-Retamozo, V., Van Xong, H., Wyns, L., Senter, P., Revets, H., De Baetselier, P., Muyldermans, S., & Magez, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307341200 · Cited by 276
Self-citationDesign and application of diabodies, triabodies and tetrabodies for cancer targeting
Todorovska, A., Roovers, R. C., Dolezal, O., Kortt, A. A., Hoogenboom, H. R., & Hudson, P. J. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00342-2 · Cited by 272
Aggregation-resistant domain antibodies selected on phage by heat denaturation
Jespers, L., Schon, O., Famm, K., & Winter, G. (2004) · Nature Biotechnology · doi:10.1038/nbt1000 · Cited by 266
Efficient tumor targeting by single‐domain antibody fragments of camels
Cortez‐Retamozo, V., Lauwereys, M., Hassanzadeh Gh., G., Gobert, M., Conrath, K., Muyldermans, S., De Baetselier, P., & Revets, H. (2002) · International Journal of Cancer · doi:10.1002/ijc.10212 · Cited by 260
Self-citationMuruganandam, A., Tanha, J., Narang, S., & Stanimirovic, D. (2002) · The FASEB Journal · doi:10.1096/fj.01-0343fje · Cited by 260
A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme
Dumoulin, M., Last, A. M., Desmyter, A., Decanniere, K., Canet, D., Larsson, G., Spencer, A., Archer, D. B., Sasse, J., Muyldermans, S., et al. (2003) · Nature · doi:10.1038/nature01870 · Cited by 246
Self-citationGreen, L. L. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00137-4 · Cited by 229 · cited 1×
“Modern strategies now allow the selection of fully human antibodies directly from natural or synthetic repertoires, including transgenic mice producing purely human antibodies [19-20].”
BackgroundSundaresan, G., Yazaki, P. J., Shively, J. E., Finn, R. D., Larson, S. M., Raubitschek, A. A., Williams, L. E., Chatziioannou, A. F., Gambhir, S. S., & Wu, A. M. (2003) · PubMed · Cited by 222
Harmsen, M. M., Ruuls, R. C., Nijman, I. J., Niewold, T. A., Frenken, L. G. J., & de Geus, B. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00081-x · Cited by 217
Low, N. M., Holliger, P., & Winter, G. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0406 · Cited by 216
Choy, E. H. S. (2002) · Rheumatology · doi:10.1093/rheumatology/41.10.1133 · Cited by 213
Junghans, R. P. (1997) · Immunologic Research · doi:10.1007/bf02786322 · Cited by 205
Willuda, J., Honegger, A., Waibel, R., Schubiger, P. A., Stahel, R. A., Zangemeister‐Wittke, U., & Plückthun, A. (1999) · PubMed · Cited by 200
Thermal Unfolding of a Llama Antibody Fragment: A Two-State Reversible Process
Pérez, J. M. J., Renisio, J. G., Prompers, J. J., van Platerink, C. J., Cambillau, C., Darbon, H., & Frenken, L. G. J. (2001) · Biochemistry · doi:10.1021/bi0009082 · Cited by 199
Immunomodulation of enzyme function in plants by single-domain antibody fragments
Jobling, S. A., Jarman, C., Teh, M.-M., Holmberg, N., Blake, C., & Verhoeyen, M. E. (2003) · Nature Biotechnology · doi:10.1038/nbt772 · Cited by 186
Biophysical Properties of Camelid VHH Domains Compared to Those of Human VH3 Domains
Ewert, S., Cambillau, C., Conrath, K., & Plückthun, A. (2002) · Biochemistry · doi:10.1021/bi011239a · Cited by 184
Emergence and evolution of functional heavy-chain antibodies in Camelidae
Conrath, K. E., Wernery, U., Muyldermans, S., & Nguyen, V. K. (2003) · Developmental & Comparative Immunology · doi:10.1016/s0145-305x(02)00071-x · Cited by 176
Self-citationZhang, J., Tanha, J., Hirama, T., Khieu, N. H., To, R., Tong-Sevinc, H., Stone, E., Brisson, J.-R., & Roger MacKenzie, C. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.09.034 · Cited by 171
Three Camelid VHH Domains in Complex with Porcine Pancreatic α-Amylase
Desmyter, A., Spinelli, S., Payan, F., Lauwereys, M., Wyns, L., Muyldermans, S., & Cambillau, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202327200 · Cited by 171
Self-citationX-Ray Crystallography of Antibodies
Padlan, E. A. (1996) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60488-x · Cited by 165
Decanniere, K., Desmyter, A., Lauwereys, M., Ghahroudi, M. A., Muyldermans, S., & Wyns, L. (1999) · Structure · doi:10.1016/s0969-2126(99)80049-5 · Cited by 164
Self-citationCamelid Heavy-Chain Variable Domains Provide Efficient Combining Sites to Haptens
Spinelli, S., Frenken, L. G. J., Hermans, P., Verrips, T., Brown, K., Tegoni, M., & Cambillau, C. (2000) · Biochemistry · doi:10.1021/bi991830w · Cited by 163
Bispecific antibodies in cancer therapy
Segal, D. M., Weiner, G. J., & Weiner, L. M. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00015-1 · Cited by 161
Single domain antibodies: comparison of camel VH and camelised human VH domains
Riechmann, L., & Muyldermans, S. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00138-6 · Cited by 160
Self-citationThe production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi
Joosten, V., Lokman, C., van den Hondel, C. A. M. J. J., & Punt, P. J. (2003) · Microbial Cell Factories · doi:10.1186/1475-2859-2-1 · Cited by 159
‘Camelising’ human antibody fragments: NMR studies on VH domains
Davies, J., & Riechmann, L. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)80432-x · Cited by 158
Proenzyme Forms of Prostate-Specific Antigen in Serum Improve the Detection of Prostate Cancer
Mikolajczyk, S. D., Catàlona, W. J., Evans, C. L., et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.026823 · Cited by 156
Davies, J., & Riechmann, L. (1996) · Protein Engineering Design and Selection · doi:10.1093/protein/9.6.531 · Cited by 155
Streltsov, V. A., Varghese, J. N., Carmichael, J. A., Irving, R. A., Hudson, P. J., & Nuttall, S. D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403509101 · Cited by 154
The crystal structure of a llama heavy chain variable domain
Spinelli, S., Frenken, L. A. M., Bourgeois, D., de Ron, L., Bos, W., Verrips, T. C., Anguille, C., Cambillau, C., & TEGONI, M. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0996-752 · Cited by 149
Saerens, D., Kinne, J., Bosmans, E., Wernery, U., Muyldermans, S., & Conrath, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409292200 · Cited by 148
Self-citationImmunogenicity of therapeutic monoclonal antibodies.
Pendley, C. E., Schantz, A., & Wagner, C. (2003) · PubMed · Cited by 147
Nguyen, V. K., HAMERS, R., Wyns, L., & Muyldermans, S. (1999) · Molecular Immunology · doi:10.1016/s0161-5890(99)00067-x · Cited by 138
Self-citationSáez‐Llorens, X., Castaño, E., Null, D. M., Steichen, J. J., Sánchez, P. J., Ramilo, O., Top, F. H., & Connor, E. M. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199809000-00007 · Cited by 136
Webster, D. M., Henry, A. H., & Rees, A. R. (1994) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(94)90070-1 · Cited by 135
Visintin, M., Settanni, G., Maritan, A., Graziosi, S., Marks, J. D., & Cattaneo, A. (2002) · Journal of Molecular Biology · doi:10.1006/jmbi.2002.5392 · Cited by 135
Yau, K. Y. F., Groves, M. A. T., Li, S., Sheedy, C., Lee, H., Tanha, J., MacKenzie, C. R., Jermutus, L., & Hall, J. C. (2003) · Journal of Immunological Methods · doi:10.1016/j.jim.2003.07.011 · Cited by 132
Gura, T. (2002) · Nature · doi:10.1038/417584a · Cited by 131
Tanha, J., Dubuc, G., Hirama, T., Narang, S. A., & MacKenzie, C. R. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(02)00027-3 · Cited by 124
Crystal Structure of the Intrinsically Flexible Addiction Antidote MazE
Loris, R., Marianovsky, I., Lah, J., Laeremans, T., Engelberg–Kulka, H., Glaser, G., Muyldermans, S., & Wyns, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302336200 · Cited by 123
Self-citationEwert, S., Honegger, A., & Plückthun, A. (2003) · Biochemistry · doi:10.1021/bi026448p · Cited by 112
Recombinant antibodies for cancer diagnosis and therapy
Souriau, C., & Hudson, P. J. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.2.305 · Cited by 111
Nielsen, U. B., Adams, G. P., Weiner, L. M., et al. (2000) · PubMed · Cited by 110
Decanniere, K., Muyldermans, S., & Wyns, L. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3839 · Cited by 110
Self-citationEngineering Antibodies for Therapy
Presta, L. G. (2002) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023378256 · Cited by 105
Prolonged in Vivo Residence Times of Antibody Fragments Associated with Albumin
Smith, B. J., Popplewell, A. G., Athwal, D., Chapman, A. P., Heywood, S. P., West, S. M., Carrington, B., Nesbitt, A. M., Lawson, A. D. G., Antoniw, P., et al. (2001) · Bioconjugate Chemistry · doi:10.1021/bc010003g · Cited by 105
Pleschberger, M., Saerens, D., Weigert, S., Sleytr, U. B., Muyldermans, S., Sára, M., & Egelseer, E. M. (2004) · Bioconjugate Chemistry · doi:10.1021/bc049964w · Cited by 104
Self-citationCamel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate
Transue, T. R., Genst, E. D., Ghahroudi, M. A., Wyns, L., & Muyldermans, S. (1998) · Proteins Structure Function and Bioinformatics · Cited by 103
Self-citationStructural tolerance of bacterial autotransporters for folded passenger protein domains
Veiga, E., de Lorenzo, V., & Fernández, L. Á. (2004) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04014.x · Cited by 100
Huls, G. A., Heijnen, I., Cuomo, M. E., Koningsberger, J. C., Wiegman, L., Boel, E. C. H., de Vries, A.-R. V. D. V., Loyson, S. A. J., Helfrich, W., Henegouwen, G. P. V. B., et al. (1999) · Nature Biotechnology · doi:10.1038/7023 · Cited by 95
Lateral recognition of a dye hapten by a llama VHH domain
Spinelli, S., Tegoni, M., Frenken, L. G. J., van Vliet, C., & Cambillau, C. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4856 · Cited by 93
Aires‐da‐Silva, F., Santa‐Marta, M., Freitas‐Vieira, A., Mascarenhas, P., Barahona, I., Moniz‐Pereira, J., Gabuzda, D. H., & Gonçalves, J. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.04.062 · Cited by 91
Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease
Martin, F., Volpari, C., Steinkühler, C., Dimasi, N., Brunetti, M., Biasiol, G., Altamura, S., Cortese, R., Francesco, R. D., & Sollazzo, M. (1997) · Protein Engineering Design and Selection · doi:10.1093/protein/10.5.607 · Cited by 89
Optimal Design Features of Camelized Human Single-domain Antibody Libraries
Tanha, J., Xu, P., Chen, Z., Ni, F., Kaplan, H. A., Narang, S. A., & MacKenzie, C. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100770200 · Cited by 82
Reiter, Y., Schuck, P., Boyd, L. F., & Plaksin, D. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2923 · Cited by 79
Woolven, B. P., Frenken, L. G. J., van der Logt, P., & NICHOLLS, P. J. (1999) · Immunogenetics · doi:10.1007/s002510050694 · Cited by 78
Molecular Recognition Properties of FN3 Monobodies that Bind the Src SH3 Domain
Karatan, E., Merguerian, M., Han, Z., Scholle, M. D., Koide, S., & Kay, B. K. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.009 · Cited by 74
Formatting antibody fragments to mediate specific therapeutic functions
Weir, A. N. C., Nesbitt, A. M., Chapman, A. P., Popplewell, A. G., & Lawson, A. D. G. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300512 · Cited by 73
Trials and tribulations: Oncological antibody imaging comes to the fore
Zuckier, L. S., & DeNardo, G. L. (1997) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(97)80033-5 · Cited by 72
A Review of Interleukin‐2 Receptor Antagonists in Solid Organ Transplantation
Berard, J. L., VELEZ, R., Freeman, R. B., & Tsunoda, S. M. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.15.1127.30582 · Cited by 66
Antigen‐independent selection of stable intracellular single‐chain antibodies
der Maur, A. A., Escher, D., & Barberis, A. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)03101-5 · Cited by 65
Frenken, L. G. J., Hessing, J. G. M., van den Hondel, C. A. M. J. J., & Verrips, C. T. (1998) · Research in Immunology · doi:10.1016/s0923-2494(98)80011-4 · Cited by 64
Groothuis, J. R., & Nishida, H. (2002) · Pediatrics International · doi:10.1046/j.1442-200x.2002.01558.x · Cited by 62
Pleschberger, M., Neubauer, A., Egelseer, E. M., Weigert, S., Lindner, B., Sleytr, U. B., Muyldermans, S., & Sára, M. (2003) · Bioconjugate Chemistry · doi:10.1021/bc025603+ · Cited by 60
Self-citationIntrabodies as therapeutic agents
Kontermann, R. E. (2004) · Methods · doi:10.1016/j.ymeth.2004.04.002 · Cited by 58
Riechmann, L. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0373 · Cited by 57
Ledeboer, A. M., Bezemer, S., de Haard, J. J. W., Schäffers, I. M., Verrips, C. T., van Vliet, C., Düsterhöft, E., Zoon, P., Moineau, S., & Frenken, L. G. J. (2002) · Journal of Dairy Science · doi:10.3168/jds.s0022-0302(02)74204-5 · Cited by 55
Bender, E., Woof, J. M., Atkin, J. D., Barker, M. D., Bebbington, C. R., & Burton, D. R. (1993) · Human Antibodies · doi:10.3233/hab-1993-4205 · Cited by 52
Improved production and function of llama heavy chain antibody fragments by molecular evolution
van der Linden, R. H. J., de Geus, B., Frenken, L. G. J., Peters, H., & Verrips, C. T. (2000) · Journal of Biotechnology · doi:10.1016/s0168-1656(00)00274-1 · Cited by 51
Production of Novel Recombinant Single-Domain Antibodies against Tandem Repeat Region of MUC1 Mucin
Rahbarizadeh, F., Rasaee, M. J., Moghadam, M. F., Allameh, A., & Sadroddiny, E. (2004) · Hybridoma and Hybridomics · doi:10.1089/1536859041224334 · Cited by 49
Hufton, S. E., van Neer, N., van den Beucken, T., Desmet, J., Sablon, E., & Hoogenboom, H. R. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01701-4 · Cited by 48
Dekker, S., Toussaint, W., Panayotou, G., de Wit, T., Visser, P., Grosveld, F. G., & Drabek, D. (2003) · Journal of Virology · doi:10.1128/jvi.77.22.12132-12139.2003 · Cited by 45
Vranken, W., Tolkatchev, D., Xu, P., Tanha, J., Chen, Z., Narang, S. A., & Ni, F. (2002) · Biochemistry · doi:10.1021/bi012169a · Cited by 44
Robert, B., Dorvillius, M., Buchegger, F., Garambois, V., Mani, J. C., Pugni�res, M., Mach, J., & P�legrin, A. (1999) · International Journal of Cancer · Cited by 42
Renisio, J., Pérez, J. M. J., Czisch, M., Guenneugues, M., Bornet, O., Frenken, L. G. J., Cambillau, C., & Darbon, H. (2002) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.10096 · Cited by 38
van Koningsbruggen, S., de Haard, H., de Kievit, P., Dirks, R. W., van Remoortere, A., Groot, A. J., van Engelen, B. G. M., den Dunnen, J. T., Verrips, C. T., Frants, R. R., et al. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00232-1 · Cited by 36
Panaccione, R., Fedorak, R. N., Anmais, G., Bernstein, C. N., Bitton, A., Croitoru, K., Enns, R. A., Feagan, B. G., Fishman, M., Greenberg, G. R., et al. (2004) · Canadian Journal of Gastroenterology · doi:10.1155/2004/670161 · Cited by 32
Solution properties ofEscherichia coli-expressed VH domain of anti-neuraminidase antibody NC41
Kortt, A. A., Guthrie, R. E., Hinds, M. G., Power, B. E., Ivancic, N., Caldwell, J. B., GRUEN, L. C., Norton, R. S., & Hudson, P. J. (1995) · Journal of Protein Chemistry · doi:10.1007/bf01980329 · Cited by 26
Two-step immunological approaches for imaging and therapy.
Rosebrough, S. F. (1996) · PubMed · Cited by 26
Generation of Bispecific and Tandem Diabodies
Kipriyanov, S. M. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-302-2_14 · Cited by 25
Voordijk, S., Hansson, T., Hilvert, D., & van Gunsteren, W. F. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3890 · Cited by 23
Expression of VHH Antibody Fragments in Saccharomyces cerevisiae
van der Vaart, J. M. (2003) · Humana Press eBooks · doi:10.1385/1-59259-240-6:359 · Cited by 18
Cited by
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809
“Similar to conventional VH domains, VHHs contain four framework regions (FRs) that form the core structure of the immunoglobulin domain and three complementarity-determining regions (CDRs) that are involved in antigen binding.”
BackgroundPEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time
Kooijmans, S. A. A., Fliervoet, L. A. L., van der Meel, R., Fens, M. H. A. M., Heijnen, H. F. G., van Bergen en Henegouwen, P. M. P., Vader, P., & Schiffelers, R. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.009 · Cited by 625
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
“As recombinant proteins, VHH are designated single-domain antibodies or nanobodies (4) in reference to their small size in the nanometer range (20, 21).”
BackgroundA robust pipeline for rapid production of versatile nanobody repertoires
Fridy, P. C., Li, Y., Keegan, S., Thompson, M. K., Nudelman, I., Scheid, J. F., Oeffinger, M., Nussenzweig, M. C., Fenyö, D., Chait, B. T., et al. (2014) · Nature Methods · doi:10.1038/nmeth.3170 · Cited by 499
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Metadata
- Authors
- Revets, H., De Baetselier, P., & Muyldermans, S.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2005-01
- Volume
- 5
- Issue
- 1
- Pages
- 111-124
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2117218524
- Cited by
- 254
- References
- 130
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.